Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Pediatric Recurrent or Refractory CNS Tumors
NCT00095940Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib in medulloblastoma, malignant glioma and ependymoma, sponsored by National Cancer Institute. Primary endpoints: Relative Phosphorylation of ERBB2 and Number of Participants With a Sustained Objective Response (Complete or Partial Response) up to 2 years. Started Oct 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
medulloblastomamalignant gliomaependymoma
Beyond the preview
Go deeper on NCT00095940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095940.